|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Polo-like kinase 1,a new therapeutic target in hepatocellular carcinoma显示文摘AIM:To investigate the role of polo-like kinase 1 (PLK1) as a therapeutic target for hepatocellular carcinoma (HCC).METHODS:PLK1 gene expression was evaluated in HCC tissue and HCC cell lines.Gene knockdown with short-interfering RNA (siRNA) was used to study PLK1 gene and protein expression using real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting,and cell proliferation using 3-(4,5-dim ethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulf ophenyl)-2H-tetrazolium (MTS) and bromodeoxyuridine (BrdU) assays.Apoptosis was evaluated using the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay,and caspase-inhibition assay.Huh-7 cells were transplanted into nude mice and co-cultured with PLK1 siRNA or control siRNA,and tumor progression was compared with controls.RESULTS:RT-PCR showed that PLK1 was overexpressed 12-fold in tumor samples compared with controls,and also was overexpressed in Huh-7 cells.siRNA against PLK1 showed a reduction in PLK1 gene and protein expression of up to 96% in Huh-7 cells,and a reduction in cell proliferation by 68% and 92% in MTS and BrdU cell proliferation assays,respectively.There was a 3-fold increase in apoptosis events,and TUNEL staining and caspase-3 assays suggested that this was caspase-independent.The pan-caspase inhibitor Z-VAD-FMK was unable to rescue the apoptotic cells.Immnofluorescence co-localized endonuclease-G to fragmented chromosomes,implicating it in apoptosis.Huh-7 cells transplanted subcutaneously into nude mice showed tumor regression in siPLK1-treated mice,but not in controls.CONCLUSION:Knockdown of PLK1 overexpression in HCC was shown to be a potential therapeutic target,leading to apoptosis through the endonuclease-G pathway. | Wei Chuen Mok Shanthi Wasser Theresa Tan Seng Gee Lim | 2012 | World Journal of Gastroenterology2012，18，27： | 4 |
| 2 | Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B显示文摘 | Sudhakar Kundapur Venkatesh Gang Wang Seng Gee Lim Aileen Wee | 2014 | European Radiology2014，，1： | 4 |
| 3 | Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years显示文摘 | Stephanos J. Hadziyannis Nicolaos C. Tassopoulos E. Jenny Heathcote Ting–Tsung Chang George Kitis Mario Rizzetto Patrick Marcellin Seng Gee Lim Zachary Goodman Jia Ma Carol L. Brosgart Katyna Borroto–Esoda Sarah Arterburn Steven L. Chuck | 2006 | Gastroenterology2006，，6： | 3 |
| 4 | Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions显示文摘 | Sang Hoon Ahn Henry L. Y. Chan Pei-Jer Chen Jun Cheng Mahesh K. Goenka Jinlin Hou Seng Gee Lim Masao Omata Teerha Piratvisuth Qing Xie Hyung Joon Yim Man-Fung Yuen | 2010 | Hepatology International2010，，1： | 3 |
| 5 | Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years显示文摘 | Stephanos J. Hadziyannis Nicolaos C. Tassopoulos E. Jenny Heathcote Ting–Tsung Chang George Kitis Mario Rizzetto Patrick Marcellin Seng Gee Lim Zachary Goodman Jia Ma Carol L. Brosgart Katyna Borroto–Esoda Sarah Arterburn Steven L. Chuck | 2006 | Gastroenterology2006，，6： | 2 |
| 6 | Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study显示文摘 | Yin-Mei Lee How Cheng Low Lee Guan Lim Yock Young Dan Myat Oo Aung Chee Leong Cheng Aileen Wee Seng Gee Lim Khek Yu Ho | 2012 | Gastrointestinal Endoscopy2012，，4： | 2 |
| 7 | Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings显示文摘AIM:To use existing hepatitis C virus(HCV)antiviral therapies as access to new treatments is limited.METHODS:A Pub Med search for randomised control trials or meta-analysis related to response-guided therapy of HCV genotype 1 patients was undertaken using pegylated interferon and ribavirin(PR),boceprevir(B)and telaprevir(T)and lead-in where responseguided therapy at TW4(TW4),8(TW8),10(TW10),or12(TW12)based on HCVRNA(+)or HCVRNA(-).Studies presented at major conferences were also used.Where necessary,a post-hoc analysis was performed.A response-guided management roadmap was created based on sustained virological response(SVR).RESULTS:Starting with PR,those with HCVRNA(-)at TW4 have>86%SVR,while those are HCVRNA(+)have 34%-41.7%SVR.HCVRNA(-)TW4 patients can have 24 wk PR if HCVRNA<400000 IU/m L.Alternatively,28 wk BPR has similar SVR.If HCVRNA(+)at TW4,72 wk PR leads to 53%SVR,hence BPR is a better option,and if HCVRNA(-)by TW8,28 wk therapy is sufficient.If HCVRNA(+)at TW8,then HCVRNA should be checked at TW10 and TW12.By TW12,HCVRNA≥100 IU/m L activates the stopping rule.This roadmap is applicable for treatment-na?ve,treatment failures and cirrhotic patients.Validation from an Asia Pacific early access boceprevir program confirmed the findings that HCVRNA(-)at TW4,or TW8 conferred>80%SVR,leading to the'80-80'rule.CONCLUSION:Using a roadmap based on HCVRNA(-)at TW4 or TW8(the'80-80'rule),high SVR can be achieved,and guide the best choices for treatment,and also reduces drug exposure in poor responders. | Seng Gee Lim | 2015 | World Journal of Gastroenterology2015，21，6： | 2 |
| 8 | Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B显示文摘 | Edward J. Gane Gilbert Deray Yun-Fan Liaw Seng Gee Lim Ching-Lung Lai Jens Rasenack Yuming Wang George Papatheodoridis Adrian Di Bisceglie Maria Buti Didier Samuel Alkaz Uddin Sophie Bosset Aldo Trylesinski | 2014 | Gastroenterology2014，，1： | 2 |
| 9 | Coexistence of Helicobacter pylori spiral and coccoid forms in experimental mice显示文摘AbstractAIMToinfectmicewithHelicobacterpylorianddetectimmuneresponseagainsttwoformsofH.pylori.METHODSAnisolateofH.pyloriobtai... | HUA Jiesong 1, HO Bow 1, ZHENG Pengyuan 1, YEOH Khay Guan 2, NG Han Chong 1 and LIM Seng Gee 2 | 1998 | World Journal of Gastroenterology1998，4，6： | 2 |
| 10 | Search for a cure for chronic hepatitis B infection: How close are we?显示文摘Chronic hepatitis B(CHB) remains a significant unmet medical need, with 240 million chronically infected persons worldwide. It can be controlled effectively with either nucleoside/nucleotide-based or interferonbased therapies. However, most patients receiving these therapies will relapse after treatment withdrawal. During recent years, the advances in molecular biology and immunology have enabled a better understanding of the viral-host interaction and inspired new treatment approaches to achieve either elimination of the virus from the liver or durable immune control of the infection. This review aims to provide a brief overview on the potential new therapies that may overcome the challenge of persistent CHB infection in the near future. | Wah Wah Phyo Alex Yu Sen Soh Seng Gee Lim Guan Huei Lee | 2015 | World Journal of Hepatology2015，7，9： | 2 |
| 11 | A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B显示文摘 | Anthony T. Tan Sarene Koh Winnie Goh Heng Yee Zhe Adam J. Gehring Seng Gee Lim Antonio Bertoletti | 2009 | Journal of Hepatology2009，，3： | 1 |
| 12 | Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years显示文摘 | Stephanos J. Hadziyannis Nicolaos C. Tassopoulos E. Jenny Heathcote Ting–Tsung Chang George Kitis Mario Rizzetto Patrick Marcellin Seng Gee Lim Zachary Goodman Jia Ma Carol L. Brosgart Katyna Borroto–Esoda Sarah Arterburn Steven L. Chuck | 2006 | Gastroenterology2006，，6： | 1 |
| 13 | Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion显示文摘 | Yan Cheng Stephane Guindon Allen Rodrigo Lin Ying Wee Masafumi Inoue Alex J V Thompson Stephen Locarnini Seng Gee Lim | 2013 | Gut2013，，9： | 1 |
| 14 | Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy显示文摘 | Yan Cheng Stephane Guindon Allen Rodrigo Seng Gee Lim | 2012 | Journal of Hepatology2012，，： | 1 |
| 15 | Viral Quasi-Species Evolution During Hepatitis Be Antigen Seroconversion显示文摘 | Seng Gee Lim Yan Cheng Stephane Guindon Bee Leng Seet Lay Yong Lee Peizhen Hu Shanthi Wasser Frank Josef Peter Theresa Tan Matthew Goode Allen Gerard Rodrigo | 2007 | Gastroenterology2007，，3： | 1 |
| 16 | Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years显示文摘 | Stephanos J. Hadziyannis Nicolaos C. Tassopoulos E. Jenny Heathcote Ting–Tsung Chang George Kitis Mario Rizzetto Patrick Marcellin Seng Gee Lim Zachary Goodman Jia Ma Carol L. Brosgart Katyna Borroto–Esoda Sarah Arterburn Steven L. Chuck | 2006 | Gastroenterology2006，，6： | 1 |
| 17 | Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance显示文摘AIM: To investigate the accuracy of serum alanine aminotransferase (ALT) in diagnosing lamivudine resistance and factors that contributed to abnormal serum ALT.METHODS: This was a retrospective study of chronic hepatitis B patients on lamivudine therapy who were followed for 3-mo with liver function tests and hepatitis B virus (HBV) DNA measurement. Lamivudine resistance was defined as HBV DNA ≥ 1 log from nadir on at least 2 occasions, confirmed by genotyping. Serum ALT levels in patients with lamivudine resistance were compared to serum ALT levels in those without lamivudine resistance. RESULTS: There were 111 patients with and 117 without lamivudine resistance. The area under the receiver operating characteristic of serum ALT to diagnose lamivudine resistance was 0.645 ± 0.037. Serum ALT > 42.5 U/L gave the best diagnostic accuracy with sensitivity = 61%, specificity = 60%, positive predictive value = 60%, negative predictive value = 61%, positive likelihood ratio = 1.53 and negative likelihood ratio = 0.65 for predicting lamivudine resistance, missing 39% of resistant patients. Using other serum ALT cutoffs, diagnostic accuracy was lower. By multivariate analysis, baseline abnormal serum ALT was associated with abnormal ALT during resistance (OR = 5.98, P = 0.003), and males were associated with serum ALT flares during resistance (OR = 8.9, P = 0.016). CONCLUSION: Serum ALT is inadequate for diagnosing lamivudine resistance and has implications where viral resistance testing is suboptimal and for reimbursement of rescue therapy. | Lee Guan Lim Myat Oo Aung Bee Leng Seet Cindy Tan Yock Young Dan Yin Mei Lee Dede Selamat Sutedja Mark Fernandes Guan Huei Lee Evelyn Koay Seng Gee Lim | 2010 | World Journal of Gastroenterology2010，16，37： | 1 |
| 18 | Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries显示文摘 | Yock Young Dan John B. Wong Saeed S. Hamid Kwang-Hyub Han Ji Dong Jia Chun-Jen Liu Teerha Piratvisuth Anna S. F. Lok Seng Gee Lim | 2014 | Hepatology International2014，，3： | 1 |
| 19 | Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma显示文摘 | Adam J. Gehring Zi Zong Ho Anthony T. Tan Myat Oo Aung Kang Hoe Lee Kai Chah Tan Seng Gee Lim Antonio Bertoletti | 2009 | Gastroenterology2009，，： | 1 |
| 20 | The Economics of Treating Chronic Hepatitis B in A- sia 显示文摘 | YOCK YOUNG DAN MYAT OO AUNG SENG GEE LIM | 2008 | Hepatology International2008，2，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员